Stockwatch: The Canadian patient
This article was originally published in Scrip
It has not been a good week for Canadian biotech. The sell-off of the crown jewels at QLT (scripintelligence.com, 25 September 2012), the return of rights to Cardiome (scripintelligence.com, 27 September 2012), the loss of a court case at Tekmira and the failure to receive fast-track NDA status at Aeterna Zentaris have left biotech investors north of the border wondering if there is much of a home-grown sector left.
You may also be interested in...
Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions
Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.
Stock Watch: The Transatlantic Asymmetries Of Generic Drugs
Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.